224785-90-4 Vardenafil AKSci E429
 
 
Loading Please Wait...
  E429    
Vardenafil
, >98% (HPLC)
 
Levitra, Vivanza




IDENTITY
CAS Number:224785-90-4
MDL Number:MFCD07773094
MF:C23H32N6O4S
MW:488.6
EINECS:607-088-5
SPECIFICATIONS & PROPERTIES
Purity:>98% (HPLC)
Spectra:LCMS, HPLC
Physical Form:White to off-white powder
Melting Point:236-239°C
Long-Term Storage:Store at room temperature
UN #:Not hazmat

BIOLOGICAL INFO
Solubility:Water: 3.5mg/L (25°C)
Application(s):Phosphodiesterase 5 (PDE5) Inhibitor; Vasodilator Agent
Form:Free Base

REVIEW

 Vardenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by vardenafil enhances erectile function by increasing the amount of cGMP.

REFERENCES
[1]Dimitriadis F, Tsampalas S, Tsounapi P, Giannakis D, Chaliasos N, Baltogiannis D, Miyagawa I, Saito M, Takenaka A, Sofikitis N (2012). Effects of phosphodiesterase-5 inhibitor vardenafil on testicular androgen-binding protein secretion, the maintenance of foci of advanced spermatogenesis and the sperm fertilising capacity in azoospermic men. Andrologia. 44 Suppl 1:144-53. PMID 21793866.
[2] Reneerkens OA, Rutten K, Akkerman S, Blokland A, Shaffer CL, Menniti FS, Steinbusch HW, Prickaerts J (2012). Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms. Neurobiol Learn Mem. 97(4):370-9. PMID 22426465.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


RELATED PRODUCTS
E429Vardenafil
F755Vardenafil hydrochloride

Current as of January 18, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > PDE5 Inhibitors


PubChem